BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Medivation, Inc. (NQ: MDVN)
59.76 USD  -2.82 (-4.51%)
Streaming Delayed Price  /  Updated: 10:28 AM EDT, Apr 23, 2014  /  Add to My Watchlist      
(MDVN) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 23, 2014
(Stock Blog Hub, 1/2/13)
We recently reiterated a Neutral recommendation on Medivation, Inc. (MDVN). Medivation received a major boost in late August when the FDA approved its prostate cancer treatment,...(read more)
(Stock Blog Hub, 1/15/13)
Everyone loves the long ball. Home runs are exciting. Sammy Sosa and Mark McGwire’s steroid-fueled race in 1998 brought baseball back from the damage caused by...(read more)
(market folly, 8/28/12)
Andreas Halvorsen's hedge fund firm Viking Global recently filed a 13G with the SEC on shares of Medivation (MDVN).  Per the filing, Viking has revealed a 5.3% ownership stake in MDVN with just...(read more)
Medivation (MDVN) Company Overview

There is no analysis for MDVN yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here